$3.05
+0.14 (+4.81%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PEPG is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 11 tracked-famous managers (VIKING GLOBAL INVESTORS LP, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, +6 more) · FINRA short interest 6.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)NCT07220603Safety and tolerability as assessed by number of participants with Adverse Events (AEs)Open-label · Treatment | Phase 2 | Recruiting | Drug: PGN-EDODM1 | Myotonic Dystrophy 1 | 48 | Jan 2029 | ≤ 895 d | 2026-03-30 |
| A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1NCT06667453Safety and tolerability as assessed by number of participants with Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: PGN-EDODM1 · Other: Placebo | Myotonic Dystrophy 1 | 24 | Mar 2027 | ≤ 223 d | 2026-07-29 |
| Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1NCT06204809Number of participants with Adverse Events, Serious Adverse Events, with abnormal Clinical Laboratory tests, abnormal ECGs, and abnormal Vital SignsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: PGN-EDODM1 for infusion · Other: Placebo | Myotonic Dystrophy 1 | 24 | 2025-10-28actual | — | 2026-02-13 |
| A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping TreatmentNCT06079736Adverse events and serious adverse events (safety and tolerability of PGN-EDO51 in MAD period)Non-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: PGN-EDO51 development terminated by Sponsor | Drug: PGN-EDO51 | Duchenne Muscular Dystrophy | 7 | 2025-08-28actual | — | 2025-12-02 |
| A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping TreatmentNCT06833931Adverse events and serious adverse events (safety and tolerability of PGN-EDO51 during the MAD period)Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Global PGN-EDO51 development voluntarily discontinued by Sponsor | Drug: IV infusion · Other: Placebo | Duchenne Muscular Dystrophy (DMD) | 0 | 2025-05-28actual | — | 2025-06-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19